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Abstract
Clinical application of potent anthracycline anticancer drugs, especially doxorubicin (DOX), is 
limited by a toxic cardiac side effect that is not fully understood and preventive strategies are yet 
to be established. Studies in genetically modified mice have demonstrated that focal adhesion 
kinase (FAK) plays a key role in regulating adaptive responses of the adult myocardium to 
pathological stimuli through activation of intracellular signaling cascades that facilitate 
cardiomyocyte growth and survival. The objective of this study was to determine if targeted 
myocardial FAK activation could protect the heart from DOX-induced de-compensation and to 
characterize the underlying mechanisms. To this end, mice with myocyte-restricted FAK knock-
out (MFKO) or myocyte-specific expression of an active FAK variant (termed SuperFAK) were 
subjected to DOX treatment. FAK depletion enhanced susceptibility to DOX-induced myocyte 
apoptosis and cardiac dysfunction, while elevated FAK activity provided remarkable 
cardioprotection. Our mechanistic studies reveal a heretofore unappreciated role for the protective 
cyclin-dependent kinase inhibitor p21 in the repression of the pro-apoptotic BH3-only protein Bim 
and the maintenance of mitochondrial integrity and myocyte survival. DOX treatment induced 
proteasomal degradation of p21, which exacerbated mitochondrial dysfunction and cardiomyocyte 
apoptosis. FAK was both necessary and sufficient for maintaining p21 levels following DOX 
treatment and depletion of p21 compromised FAK-dependent protection from DOX. These 
findings identify p21 as a key determinant of DOX resistance downstream of FAK in 
cardiomyocytes and indicate that cardiac-restricted enhancement of the FAK/p21 signaling axis 
might be an effective strategy to preserve myocardial function in patients receiving anthracycline 
chemotherapy.
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1. Introduction
The anthracycline doxorubicin (DOX) is one of the most frequently used chemotherapeutic 
agents as it is highly effective in the treatment of both solid and hematological malignancies. 
However, cumulative dose-dependent cardiac toxicity limits the therapeutic efficacy of this 
drug [1, 2]. Even with strict limitations of lifetime dosage a significant fraction of DOX-
treated patients display signs of cardiac injury. The most common and devastating 
cardiovascular risk is chronic or delayed cardiomyopathy that, once initiated, rapidly 
progresses to congestive heart failure with 1-year mortality rates approaching 50% [1, 2]. 
Acute toxicities that develop immediately after treatment (mainly due to electrical 
disturbances) or sub-acute toxicities that occur within one week following treatment are also 
quite prevalent [1, 2]. Clearly a detailed understanding of the mechanisms underlying these 
various clinical presentations will provide an opportunity to develop effective treatment 
strategies to reduce or prevent detrimental off-target effects on the cardiovascular system.
DOX exposure can trigger both cancer cell and myocyte apoptosis, and this form of myocyte 
injury has been linked to the development of both sub-acute and chronic cardiomyopathies. 
DOX forms an inactive adduct between DNA and topoisomerase II (Top2) which inhibits 
Top2-dependent strand ligation during DNA synthesis[3] and very recent studies indicate 
that Top2β is required for the adverse cardiac remodeling that accompanies chronic DOX 
treatment [4]. In rapidly cycling cancer cells inhibition of Top2 leads to accumulation of 
single- and double-strand DNA breaks and initiates a DNA damage repair pathway resulting 
in activation of the tumor suppressor, p53 and initiation of p53-dependent apoptosis[5]. 
However, it is presently unclear to what extent the DNA damage response is causal for 
initiating myocyte apoptosis following DOX treatment[6-8]. DOX also induces oxidative 
stress via the generation of reactive oxygen species (ROS) and alters iron homeostasis and 
there is evidence to support a role for each of these pathways in DOX-induced cardiac 
toxicity[1, 2]. Notably, mitochondrial dysfunction is a common consequence of DOX-
mediated genotoxic and oxidative myocyte stress and the resultant loss of mitochondrial 
membrane potential leads to cytochrome c release and activation of effector caspase-
mediated apoptosis.
Importantly, the so called intrinsic mitochondrial-mediated programmed cell death cascade 
can be reversed by activation of pro-survival signals such as those mediated by integrin-
dependent adhesive complexes. Integrins are heterodimeric cell-surface receptors composed 
of α and β subunits, which physically link extracellular matrices to the intracellular actin 
cytoskeleton and these adhesion complexes are necessary for maintaining tissue integrity, 
conveying tensile strength, and for the transduction of growth and survival signals [9]. 
Indeed, aberrant expression of integrins is associated with tumorigenesis and resistance to 
cytotoxic therapies. For example, activation of the α2β1 integrin rendered malignant T cells 
resistant to DOX-dependent apoptosis [10], while inhibition of β1 integrin signaling 
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sensitized various types of cancer cells to radiotherapy and chemotherapy[11-13]. Since 
integrins lack intrinsic kinase activity, transduction of integrin-mediated survival signals 
requires cytoplasmic signaling molecules. Focal adhesion kinase (FAK), a nonreceptor 
protein tyrosine kinase, associates with the cytoplasmic tails of all β1-containing integrins 
and its activity is critical for integrin signaling, including the signals that mediate cancer cell 
resistance to cytotoxic agents [11, 14-19].
Interestingly, we and others have shown that FAK provides critical survival signaling 
throughout cardiac development and in adult hearts when subjected to pathological stress 
[20-24]. Herein we show that mice with myocyte-restricted depletion of FAK exhibited 
exacerbated DOX-induced cardiomyopathy, while those engineered to confer enhanced 
FAK activation in cardiomyocytes exhibited remarkable cardioprotection, indicating that 
cardiac-restricted enhancement of FAK activity might be an effective strategy to preserve 
myocardial function in this setting. Our mechanistic studies reveal a heretofore 
unappreciated consequence of DOX treatment on depletion of p21Cip1 (p21). We show that 
cytoplasmic p21 is cytoprotective in cardiomyocytes, and that activation of FAK reduced 
DOX cardiotoxicity, at least in part, by up-regulation of p21.
2. Materials and Methods
An expanded Methods section is available in the online-only Data Supplement.
2.1. Animals
Myocyte-restricted FAK knockout (MFKO) mice were generated using the Cre/LoxP 
technology, and cardiac-specific SuperFAK (SF) transgenic mice (SF2) were generated 
using a myosin heavy chain promoter as described previously [20, 24, 25]. Cardiomyopathy 
was induced by a single injection of DOX (20mg/kg, i.p.) with 0.9% NaCl as a control. All 
procedures were approved by the IACUC at the University of North Carolina, Chapel Hill.
2.2. Statistics
Results are expressed as mean ± SEM. Student’s unpaired t test was used to compare values 
between 2 groups. One-way analysis of variance with the Bonferroni/Dunnett post-hoc 
analysis was used to determine the difference among multiple groups. Differences were 
considered significant at P < 0.05.
3. Results
3.1. FAK antagonizes DOX-induced cardiomyopathy
We previously showed that conditional deletion of FAK from the myocardium of adult mice 
did not affect basal cardiac performance or myocyte viability [20] but exacerbated ischemia/
reperfusion-induced cardiac stress [23]. In the present study, we sought to determine if 
endogenous FAK also plays an important cardioprotective role in chemotherapy-induced 
cardiotoxicity. To this end, we injected MFKO and wild-type (WT) littermate control mice 
with DOX (20mg/kg, i.p. bolus that was previously shown to induce sub-acute 
cardiomyopathy [26]) and monitored heart function by echocardiography for up to 5 days 
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following treatment. As shown in Figure 1A,B, DOX-induced cardiac dysfunction was 
exacerbated in MFKO mice as evidenced by a significant decrease in ejection fraction (EF) 
and fractional shortening (FS) at days 3 and 5 following treatment.
Based on these data, we predicted that enhanced activity of this intrinsic pro-survival signal 
might impart resistance to cardiac toxicity induced by DOX. FAK activation proceeds by a 
2-step process that involves integrin- or growth factor-induced dimerization and 
autophosphorylation of Tyr397 which directs Src to bind to and phosphorylate FAK on 2 
additional sites within the activation loop (Tyr576 and Tyr577) that lead to further 
augmentation of FAK activity [25]. We recently generated mice with cardiac-restricted 
expression of a super-activatable FAK variant (SuperFAK, SF) that contained mutations 
within the FAK activation loop (Lys578Glu/Lys581Glu) that mimic the charge transfer (and 
enhanced catalytic activity) induced by Src phosphorylation [24, 27]. We reported that these 
so-named SuperFAK mice (SF2) exhibited elevated allosteric activation of FAK in the 
myocardium and that these mice were protected from ischemia/reperfusion-induced cardiac 
de-compensation[24]. To determine the extent to which SuperFAK might confer resistance 
to cardiac stress induced by genotoxic agents, we treated SF2 and non-transgenic littermate 
control mice (NTG) with DOX as described above. Echocardiography revealed that DOX 
treatment impaired heart function in NTG mice as evidenced by a significant decrease in EF 
and FS at 5 and 14 days following treatment, while both parameters were well preserved in 
SF2 mice (Figure 1D,E). Hearts from NTG mice also exhibited significantly decreased end-
systolic posterior wall and intraventricular septal thickness and increased LV end-systolic 
dimension than those from similarly treated SF2 mice (Supplemental Figure 1). Since 
anthracylines commonly induce appetite suppression we also monitored body weight in 
these mice. As shown in Supplemental Figure 2A, DOX injection led to a similar extent of 
weight loss in NTG and SF2 mice, indicating that these mice experienced an equivalent 
level of stress. Collectively, these results demonstrate that FAK antagonizes DOX-induced 
cardiotoxicity in vivo.
3.2. FAK conferred resistance to DOX-induced cardiomyocyte apoptosis
To explore whether cardioprotection by FAK might result from mitigating DOX-dependent 
myocyte apoptosis, we evaluated TUNEL staining in hearts from DOX-treated mice 
(Supplemental Figure 2B). Compared with WT mice, MFKO hearts exhibited a significant 
increase in TUNEL labeling at end-stage (i.e. day 5; Figure 1C). However, a significant 
reduction in TUNEL-positive myocytes was observed in SF2 hearts when compared to 
treated littermate controls at both 1 and 14 days post-injection (Figure 1F). Moreover, DOX 
injection led to myocyte vacuolization and myofibrillar loss, which was exacerbated in 
MFKO mice, but attenuated in SF2 mice (Supplemental Figure 2C).
To uncover the signaling mechanism(s) by which FAK confers protection from anthracyline 
cardiotoxicity, we infected primary neonatal rat cardiomyocytes (NRCMs) with 
adenoviruses expressing green fluorescent protein (GFP) or SF. NRCMs are a widely used 
model system to interrogate downstream pathways in differentiated cardiomyocytes and 
importantly, previous studies determined that treatment with DOX (1 to 2μM) promotes 
apoptotic death of these cells within a 24 to 48h window [28]. As shown in Figure 2, DOX 
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induced significantly higher numbers of apoptotic GFP-expressing myocytes than SF-
expressing cells as assessed by TUNEL staining, caspase 3 cleavage, and cleavage of the 
caspase 3 substrate PARP (Figure 2A,C). As well, the metabolic capacity of SF infected 
cells was better preserved following DOX treatment as assessed by the ability of the cells to 
reduce the tetrazolium dye, MTT (Figure 2B).
We next used FAK-specific small interfering RNAs to confirm a role for endogenous FAK 
in mediating myocyte survival in this setting. As shown in Figure 2F, treatment of cultured 
cardiomyocytes with FAK siRNAs led to an approximate 90% reduction of FAK levels as 
assessed by Western analysis. While FAK depletion alone did not alter basal cell survival, it 
sensitized cardiomyocytes to DOX-dependent apoptosis as assessed by TUNEL staining, 
MTT reduction, and PARP cleavage (Figure 2D-F). Taken together, these data indicate that 
FAK activity is both necessary and sufficient to protect cardiomyocytes from DOX-induced 
programmed cell death.
3.3. FAK-dependent DOX resistance correlated with p21 levels
While several reports have shown that FAK depletion sensitizes various cancer cells to 
cytotoxic chemotherapy, the underlying mechanisms are not yet clear [29]. In some cell 
types, FAK promotes cell survival by trans-locating to the nucleus, binding to, and inducing 
the degradation of the tumor suppressor p53 [30, 31]. To determine whether a similar 
pathway is operative in cardiomyocytes, we first explored whether SF expression led to 
reduced protein levels of p53 and its transcriptional target, the cyclin-dependent kinase 
inhibitor (CDKI) p21. Contrary to reported findings in fibroblasts and tumor cells [30, 31], 
we found that p53 levels were not altered by SF expression in hearts from DOX-challenged 
mice (Supplemental Figure 3A). This discrepancy may be related to the sub-cellular locale 
of FAK in these various cell types. Indeed, the aforementioned studies indicated that nuclear 
localized FAK bound to p53 and targeted it for MDM2-dependent ubiquitination and 
degradation [30] and we have found very little nuclear FAK in cardiomyocytes 
(Supplemental Figure 3B). A somewhat surprising finding was that p21, which has been 
recently shown to confer chemoresistance to cisplatin[32], was elevated in these hearts and 
SF induced a significant and dose-dependent increase in basal levels of p21 in 
cardiomyocytes (Figure 3A and 3B). Interestingly, treatment with pifithrin-α (30 μM) fully 
attenuated p53-mediated induction of p21 but did not alter SF-mediated up-regulation of p21 
(Supplemental Figure 3C,D). In support of a critical role for endogenous FAK in the 
regulation of p21, protein levels of p21 were dramatically reduced in FAK-depleted 
cardiomyocytes in vitro and in vivo (Figure 3C,D). The half-life of p21 was similar in GFP- 
and SF-infected cardiomyocytes, suggesting that FAK does not affect p21 protein stability 
(Figure 3E, Supplemental Figure 4). Instead, we found that SF expression markedly 
increased p21 mRNA levels (Figure 3F), and subsequent experiments in which SF- or GFP-
expressing cardiomyocytes were treated with actinomycin D (5 μg/ml) revealed that elevated 
FAK activity reduced the rate of p21 mRNA degradation, suggesting that FAK signaling 
regulates p21 message stability (Figure 3G).
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3.4. p21 localized primarily to the cytoplasm of cardiomyocytes and was necessary for 
resistance to DOX-induced apoptosis
Although nuclear p21 is well known for mediating cell cycle arrest, recent reports indicate 
that cytoplasmic p21 promotes cell survival and limits the effectiveness of anticancer 
agents[32-34]. Notably, we found that p21 is predominantly cytoplasmic in NRCMs and in 
adult hearts (as assessed by sub-cellular fractionation and immunofluorescent staining; 
Figure 4A-D). To determine whether p21 plays a critical cyto-protective role in 
cardiomyocytes, we depleted p21 in NRCMs using siRNA and evaluated the induction of 
apoptosis by DOX. Similar to our findings in FAK-depleted cells (Figure 2D-F), siRNA-
mediated reduction of p21 alone did not influence cell survival (Supplemental Figure 5), but 
rendered cardiomyocytes hypersensitive to DOX-induced apoptosis as assessed by PARP 
cleavage (Figure 4E), TUNEL labeling (Figure 4F,G) and MTT reduction (Figure 4H). We 
recognize that neonatal cardiomyocytes exhibit some cell cycle activity while adult 
cardiomyocytes are post-mitotic; a difference that could be particularly important with 
respect to the function of p21. For this reason, we repeated some of our major findings in 
cardiomyocytes isolated from 10-day-old rats (which we confirmed were bi-nucleated and 
had withdrawn from the cell cycle as has been previously reported [35]). Importantly, as 
shown in Supplemental Figure 6, silencing p21 in these non-cycling cardiomyocytes also 
rendered these cells more susceptible to DOX-induced apoptosis. Together these data 
indicate that p21 functions as a pro-survival factor in stressed cardiac myocytes.
3.5. Long-term treatment with DOX induced proteasomal degradation of p21
While DOX has been reported to induce p21 transcription [36], a kinetic analysis using 
apoptotic-inducing concentrations of DOX in NRCMs showed that DOX induced an initial 
up-regulation of p21 (apparent at 4 hr post-treatment) followed by a dramatic decline below 
basal levels that was noticeable between 16 and 24 hrs post-treatment (Figure 5A). Both the 
temporal nature and dose-dependence of DOX-mediated p21 down-regulation correlated 
with the extent of cardiomyocyte apoptosis as assessed by PARP cleavage (Figure 5B,C). 
Importantly, SF expression was capable of maintaining p21 levels following DOX treatment 
in vitro and in vivo (see Figure 3B, Supplemental Figure 7). As shown above, p21 is a short-
lived protein and previous studies revealed that its turnover is tightly controlled by 
proteolytic pathways such as the proteasome pathway (Supplemental Figure 8) [37, 38]. 
Since DOX is known to activate the myocardial ubiquitin proteasome system [39], we 
reasoned that this pathway might account for the low levels of p21 apparent in DOX-treated 
cardiomyocytes. Indeed, we found that treatment of NRCMs with the 26S proteasome 
inhibitor, MG132, prevented DOX-induced down-regulation of p21, indicating that DOX 
triggered p21 degradation by the proteasome pathway (Figure 5D).
3.6. Silencing of p21 exacerbated DOX-induced mitochondrial damage
While the precise mechanisms by which DOX-treatment induces cardiomyocyte apoptosis is 
not entirely clear, altered mitochondrial energetics likely plays a causal role[1, 2]. To test the 
hypothesis that p21 confers cardio-protection from DOX treatment by limiting stress-
induced mitochondrial damage, control and p21 siRNA-treated NRCMs were subjected to 
DOX and mitochondrial membrane potential (ΔΨm) was assessed by staining with the 
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mitochondria-specific cationic dye, JC-1. JC-1 accumulates and aggregates in energized 
mitochondria (wherein it fluoresces red) but fluoresces green in its cytosolic monomeric 
form. Confocal microscopy revealed that DOX treatment induced mitochondrial membrane 
depolarization, as measured by increased ratio of JC-1 monomers/J-aggregates (Figure 
6A,B). Importantly, we found that p21 knockdown dramatically augmented DOX-induced 
mitochondrial membrane depolarization (Figure 6A,B). A major consequence of loss of 
ΔΨm is the release of cytochrome c into the cytosol which triggers the intrinsic apoptosis 
pathway via caspase activation. Accordingly, knockdown of p21 markedly increased DOX-
dependent accumulation of cytosolic cytochrome c as assessed by sub-cellular fractionation 
(Figure 6C). Collectively, these data indicate that cytoplasmic p21 functions to protect 
cardiomyocytes from DOX-dependent activation of the intrinsic mitochondrial apoptotic 
pathway.
3.7. Elevated expression of p21 mitigated DOX cardiotoxicity and repressed Bim
Knowing that p21 is a key survival factor in cardiomyocytes, we sought to further explore 
whether forced expression of exogenous p21 using an adenoviral vector promotes 
chemoresistance to DOX. Western blotting revealed that a moderate elevation in p21 levels 
inhibited DOX-induced caspase 3 cleavage (Figure 7A). Moreover, overexpression of p21 
also suppressed cell death in response to DOX treatment as assessed by TUNEL assay and 
Calcein AM/ Ethidium homodimer-1 staining (Figure 7B,C). Measurement of ΔΨm using 
JC-1 revealed that DOX-induced mitochondrial membrane depolarization was limited by 
exogenous p21 (Figure 7D). In terms of mechanism, it was recently shown that DOX 
treatment led to increased expression of the proapoptotic BH3-only protein Bim [40], which 
was required for DOX cytotoxicity[41]. Therefore we tested the hypothesis that p21 might 
attenuate DOX cardiotoxicity by modulating Bim expression. Indeed, RT-PCR revealed that 
silencing of p21 enhanced DOX-induced expression of Bim (Figure 7E), and adenoviral 
mediated p21 overexpression suppressed Bim induction by DOX (Figure 7F). Together, 
these data provide strong evidence that p21 regulates cardiomyocyte survival by preserving 
mitochondrial membrane integrity.
3.8. Knockdown of p21 compromised FAK-dependent DOX resistance
Finally, we sought to explore the extent to which elevated p21 levels account for FAK-
dependent mitigation of DOX-induced cardiac toxicity. As shown in Figure 8A, DOX 
markedly induced caspase 3-dependent PARP cleavage, which was abrogated by SF 
overexpression. However, knockdown of p21 prevented SF-mediated protection from DOX-
induced apoptosis, indicating that FAK promotes DOX resistance in cardiomyocytes, at least 
in part, by the up-regulation of p21.
4. Discussion
To date, effective strategies for the prevention of DOX-induced cardiomyopathy and heart 
failure are unavailable [2]. Increased serum troponin levels (indicative of cardiomyocyte 
death) have been detected in patients within the first 3-5 days after administration of 
standard doses of anthracyclines and early troponin release is a reliable predictor of 
subsequent diastolic dysfunction [42]. Thus it has been postulated that multiple hits of acute 
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anthracycline-induced apoptosis decreases cardiac reserve over time due to repeated acute 
loss of cardiomyocytes coupled with the limited regenerative capacity of this cell type. 
These findings highlight the importance of defining the mechanisms that control 
anthracycline-induced apoptosis as therapies that limit this response could be efficacious in 
preventing future development of refractive cardiomyopathies. Herein, for the first time, we 
identified a critical chemoresistant role of myocardial p21. We found that p21 represses 
expression of the BH3-only protein Bim and functions to protect mitochondrial integrity and 
cardiomyocyte viability and that DOX targets p21 for proteosomal degradation. Moreover, 
we found that dampened FAK activity exacerbated while elevated activity of FAK mitigated 
DOX-induced cardiomyopathy and cardiomyocyte apoptosis and that the ability of FAK to 
attenuate DOX toxicity was dependent on its ability to up-regulate p21 (see schematic, 
Figure 8C).
p21 is a universal cyclin-dependent kinase inhibitor and its overexpression can induce G1/S 
or G2/M cell cycle arrest. However, the continued expression and high abundance of this 
protein in post-mitotic cells such as cardiomyocytes supports its involvement in important 
biological processes apart from cell cycle withdrawal. Indeed, recent studies ascribe a pro-
survival function to p21, as endogenous p21 serves to protect cancer cells[32, 43-46] and 
monocytes[47] from chemotherapy-dependent execution of apoptosis. Interestingly, this 
pro-survival function was correlated with its cytoplasmic localization and accumulation of 
p21 in the cytoplasm has been linked to increased tumor aggressiveness, metastasis, and 
poor prognosis [48]. Herein we found that p21 is almost exclusively cytoplasmic in neonatal 
cardiomyocytes and in the adult heart and showed that p21 depletion sensitized 
cardiomyocytes to DOX-dependent apoptosis, indicating that endogenous p21 also plays a 
major pro-survival role in these noncycling cells. While global p21 knock-out mice were 
reportedly modestly protected from DOX-dependent cardiomyopathy [49], future studies are 
warranted in mice with myocyte-restricted p21 depletion, as the former benefit was 
associated with a dampened inflammatory response, likely because p21 contributes to 
differentiation of monocytes to macrophages [50].
In some cancer cells, the chemoresistant effects of p21 expression has been linked to its 
capacity to arrest cell cycling, which when DNA damage is present, permits cells sufficient 
time for DNA repair[32-34]. We feel that this mechanism is not likely to explain the 
cardioprotective effects of p21 shown herein, because in our system cardiomyocyte cell 
cycle entry is extremely limited. Instead, we favor a mechanism by which cytoplasmic p21 
antagonizes DOX-induced mitochondrial dysfunction. p21 has been reported to influence 
cell survival by acting both up- or down-stream of the intrinsic mitochondrial-mediated cell 
death pathway. p21 inhibits activation of CDK2/4/6 [51], kinases that induce translocation 
of Bax and Bim to the mitochondria [52, 53] and initiate mitochondrial membrane damage-
induced cell death [54]. Pharmacological inhibition of CDK4/6 was recently shown to 
antagonize the cytotoxic effect of doxorubicin in several non-cardiac cells [55, 56]. As well, 
ectopic expression of dominant-negative CDK2 or p21 attenuated apoptotic cell death in 
cardiomyocytes subjected to prolonged hypoxia [57, 58]. Our results revealed that when 
combined with DOX treatment, knockdown of p21 resulted in a dramatic and synergistic 
depolarization of cardiomyocyte mitochondrial membranes and significantly increased the 
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release of cytochrome c, indicating that endogenous p21 also functions to prevent initiation 
of the mitochondrial-death cascade in this setting. Importantly, we show that a modest up-
regulation of p21 provides acute protection from DOX-induced mitochondrial membrane 
depolarization and apoptosis. Mechanistically, we found that myocyte p21 likely preserves 
mitochondrial integrity, at least in part, by antagonizing DOX-induced expression of the 
pro-apoptotic BH3-only Bim, a protein that is critical for initiation of mitochondrial 
membrane depolarization upon the induction of apoptosis [59-61] (also see Supplemental 
Discussion).
DOX, like many DNA damaging agents, has been reported to induce expression of p21 
through a p53-dependent mechanism [62, 63]. In cardiomyocytes, we found that DOX 
regulated p21 levels in a bi-phasic fashion: an initial transient up-regulation which peaked 4 
hr after DOX exposure, followed by rapid proteasome-dependent degradation that resulted 
in a significant depletion below basal levels by 16 hr following treatment. While others have 
reported that DOX treatment leads to activation of the myocardial ubiquitin-proteasome 
system [39], our studies are the first to reveal that degradation of p21 is an important 
consequence of this event (see Supplemental Discussion for possible ubiquitin ligases 
involved). Our findings also extend previous studies which revealed that UV irradiation-
induced DNA damage signaling resulted in ubiquitin-dependent p21 degradation in 
osteosarcoma cells and normal human fibroblasts [37].
Herein we demonstrated that cardiac-specific SF transgenic mice displayed less mortality 
and better heart function accompanied by less apoptotic cardiomyocytes following DOX 
treatment, while the opposite was observed in MFKO mice. Moreover, overexpression of SF 
attenuated, and knockdown of FAK enhanced DOX-induced apoptosis in cultured 
cardiomyocytes. These results suggest for the first time that myocardial FAK activation 
promotes resistance to DOX cardiotoxicity. A potential limitation of the current study is that 
the cardiomyopathy in these animal models was induced by a single, maximum dose 
injection, which is distinct from repeated, lower dose administration in the clinic. However, 
it has been shown that chronic DOX cardiotoxicity also involves myocyte apoptosis [64], 
indicating the likelihood that similar pathways are involved. Our conclusion fits with the 
fact that FAK is frequently up-regulated in a variety of cancers, is associated with poor 
prognosis and patient survival, and that inactivation of FAK in breast cancer cells 
exaggerated DOX-induced apoptosis [11, 14-19, 65].
In conclusion, our findings indicate that levels of p21 in cardiomyocytes determine 
resistance to cardiotoxicity induced by the anthracycline DOX. Moreover, we provide 
evidence that treatments which preserve p21 levels (including those that activate FAK) may 
form the basis for the development of novel therapeutic strategies to prevent or alleviate 
genotoxic cardiotoxicities.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CDK cyclin-dependent kinase
CDKI cyclin-dependent kinase inhibitor
DOX doxorubicin
FAK focal adhesion kinase
MFKO myocyte-restricted FAK knockout mice
NRCM neonatal rat cardiomyocytes
NTG non-transgenic littermate control mice
SF Super activatible FAK variant, or SuperFAK
SF2 cardiac-specific SF transgenic mice line 2
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• Cardiac FAK depletion exacerbated DOX-induced dysfunction and myocyte 
apoptosis.
• Activation of cardiac FAK provided protection from DOX-induced toxicity.
• FAK activation preserves mitochondrial integrity by inducing p21 and Bim.
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FAK antagonizes doxorubicin (DOX)-induced cardiomyopathy and myocyte apoptosis in 
vivo. (A-C) Myocyte-restricted FAK knockout mice (MFKO, n=5) and wild-type littermate 
control mice (WT, n=9) received a single injection of DOX (20mg/kg, i.p.) and heart 
function was monitored by echocardiography before DOX injection, and at day 3 and day 5 
post DOX injection. DOX treatment led to a more pronounced decrease in ejection fraction 
(EF, A) and fractional shortening (FS, B) in MFKO compared to WT mice. (C) Myocyte 
apoptosis (measured by dual staining with TUNEL and anti-cardiac troponin T) was 
exacerbated in MFKO hearts at day 5 post DOX injection. * P<0.05; ** P<0.01 vs. WT. (D-
F) Cardiomyocyte-specific transgenic mice expressing a superactivatable variant of FAK 
(SF2, n=8) and non-transgenic littermate control mice (NTG, n=8) were treated with DOX 
as described above and heart function was monitored at baseline, and at day 5 and day 14 
post DOX injection. Both EF (D) and FS (E) were better preserved in DOX treated SF2 
mice. (F) Apoptosis was significantly reduced in SF2 hearts compared to NTG hearts at day 
1 and 14 post DOX injection. * P<0.05; ** P<0.01 vs. NTG. n=3-6 mice per group at each 
time point. Data are mean ± SEM.
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FAK is necessary and sufficient for cardiomyocyte survival in response to DOX treatment. 
(A-C) Neonatal rat cardiomyocytes (NRCM) were non-infected (NI), or infected with GFP 
or SF adenoviruses before treatment with DOX (1μM) for 24h. (A) Overexpression of SF 
attenuated cardiomyocyte apoptosis as assessed by TUNEL staining. Results are mean±SEM 
of 4 independent experiments. * P<0.05. (B) MTT reduction assay revealed that SF 
preserved metabolic activity of cardiomyocytes following DOX treatment. ** P<0.01; *** 
P<0.001. (C) Activation of FAK, as revealed by higher levels of phospho-FAK (Y397) in 
SF-expressing cells, inhibited DOX-induced cleavage of caspase 3 and its downstream 
target PARP. (D) NRCMs were transfected with control (si-Control) or FAK siRNA (si-
FAK) prior to treatment with DOX (2 μM) for 24h. TUNEL staining revealed that 
knockdown of FAK increased DOX-dependent apoptosis. Data represent mean±SEM of 4 
independent experiments. * P<0.05 vs. si-Control. (E) An MTT reduction assay revealed 
that knockdown of FAK reduced cardiomyocyte survival following DOX treatment. ** 
P<0.01. (F) NRCMs were transfected with si-Control or si-FAK before treatment with DOX 
(2 μM) for 16h. Western blotting revealed that depletion of FAK enhanced DOX-induced 
PARP cleavage.
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FAK-dependent DOX resistance correlates with p21 levels. (A) NRCMs were infected with 
vehicle, GFP, or SF adenoviruses at multiplicity of infection (MOI) of 10, 50, and 250. 
Overexpression of SF increased p21 protein levels in a dose-dependent manner. (B) SF2 
hearts maintained higher protein levels of p21 than controls at day 14 post DOX injection. 
Blots are representative of 3-5 hearts per group. (C) NRCMs were transfected with control 
(si-Control) or FAK siRNA (si-FAK). Depletion of FAK reduced p21 protein levels in 
cardiomyocytes. (D) Protein levels of p21 were lower in MFKO than in WT heart extracts at 
day 5 post DOX injection. (E) NRCMs were infected with GFP or SF adenoviruses prior to 
incubation with the protein synthesis inhibitor cycloheximide (CHX, 10μg/ml) for various 
periods of time. Western blotting revealed that activation of FAK did not alter p21 protein 
stability. (F) Semi-quantitative RT-PCR of p21 in NRCMs infected with vehicle, GFP, or 
SF adenoviruses. Overexpression of SF elevated mRNA levels of p21. Results are 
representative of 3 independent experiments. (G) Semi-quantitative RT-PCR of p21 in 
NRCMs infected with GFP, or SF adenoviruses prior to treatment with the RNA synthesis 
inhibitor actinomycin D (Act-D, 5μg/ml) for various periods of time. Overexpression of SF 
prevented degradation of p21 mRNA.
Cheng et al. Page 17























p21 localizes primarily to the cytoplasm of cardiomyocytes and is necessary for DOX 
resistance. (A) Western blotting of nuclear (Nuc) and cytosolic (Cyto) fractions from 
NRCMs. Histone H3 served as a nuclear loading control and GAPDH as a cytosolic loading 
control. (B) Immunofluorescent staining of NRCMs for p21 (green), nuclei (DAPI, blue), 
and cardiomyocyte marker α-actinin (red). Scale bar = 10μm. (C) Subcellular fractionation 
of adult mouse hearts revealed that p21 localizes predominantly to the cytosol. (D) 
Immunohistochemical staining of adult heart sections for p21 (green), cardiac troponin T 
(cTnT, red) and nuclei (DAPI, blue). Scale bar = 10μm. (E) NRCMs were transfected with 
control (si-Control) or p21 siRNA (si-p21) before treatment with DOX (2μM) for 24h. 
Western blotting revealed that depletion of p21 enhanced DOX-induced PARP cleavage. 
(F,G) NRCMs were transfected with si-Control or si-p21 before treatment with vehicle or 
DOX (1μM) for 36h. Apoptosis was evaluated by TUNEL staining. (F) Representative 
images of cells stained for TUNEL (green), nuclei (DAPI, blue), and cardiomyocyte marker 
α-actinin (red). Scale bar = 50μm. (G) Quantification of TUNEL-positive myocytes 
following DOX treatment. Data are mean±SEM of 4 independent experiments * P<0.05 vs. 
si-Control. (H) An MTT reduction assay revealed that knockdown of p21 reduced 
cardiomyocyte survival following DOX treatment. ** P<0.01.
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Long-term treatment with DOX induced proteasomal degradation of p21. (A) NRCMs were 
treated with DOX (1μM or 2μM) for various periods of time. Protein levels of p21 were 
transiently up-regulated at 4h and dramatically decreased at later time points. (B) Western 
blotting revealed that DOX-induced reduction of p21 protein levels was associated with 
apoptosis as assessed by PARP cleavage. Results are representative of 3 independent 
experiments. (C) NRCMs were treated with various doses of DOX for 24h. Again, DOX-
induced down-regulation of p21 protein was correlated with cleavage of PARP. (D) NRCMs 
were treated with DOX (1μM) for 24h without or with the addition of the 26S proteasome 
inhibitor MG132 (10μM) for 16h. Inhibition of the proteasome completely blocked DOX 
induced reduction of p21 protein levels.
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Knockdown of p21 exacerbated DOX-induced mitochondrial damage in cardiomyocytes. 
NRCMs were transfected with si-Control or si-p21 before treatment with vehicle or DOX 
(1μM) for 24h. (A,B) Cells were stained with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-
imidacarbocyanine iodide (JC-1), which selectively enters mitochondria and forms J-
aggregates (red) in healthy cells with high mitochondrial membrane potential (ΔΨm), but 
remains monomers (green) in apoptotic cells with low mitochondrial ΔΨm. (A) 
Representative images of JC-1 staining. Scale bar = 100μm. (B) Quantitative analysis of the 
ratio of JC-1 monomers / J-aggregates revealed that knockdown of p21 dramatically 
exacerbated DOX-induced mitochondrial depolarization. Results represent mean±SEM of 3 
independent experiments.* P<0.05. (C) Subcellular fractionation revealed that depletion of 
p21 enhanced DOX-induced cytochrome c release into the cytosol. Tom20 served as a 
mitochondrial loading control and GAPDH as a cytosolic loading control. Blots are 
representative of 3 independent experiments.
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Elevated p21 expression attenuates DOX cardiotoxicity and represses Bim. (A-D) NRCMs 
were infected with LacZ or p21 adenoviruses prior to treatment with DOX (1μM) for 36h. 
Expression of exogenous p21 suppressed caspase 3 cleavage (A). Cell viability was assessed 
by staining with TUNEL (B) or calcein AM/Ethidium homodimer-1 (C) as described in the 
Methods. Mitochondrial membrane depolarization was assessed by staining with JC-1 (D). 
Data are mean±SEM of 3-4 independent experiments. * P<0.05 vs. LacZ. (E) NRCMs were 
transfected with control or p21 siRNA prior to treatment with DOX (1μM) for 2h. Transcript 
levels of Bim and p21 were assessed by semi-quantitative RT-PCR. GAPDH served as a 
loading control. (F) NRCMs were infected with LacZ or p21 adenoviruses prior to treatment 
with DOX (1μM) for 2h. Expression of exogenous p21 suppressed Bim expression 
following DOX treatment.
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Cardiac FAK activation promotes DOX resistance via p21. (A) GFP- or SF-expressing 
NRCMs were transfected with control or p21 siRNA prior to treatment with DOX (1μM) for 
16h. Knockdown of p21 reversed the protection of PARP cleavage conferred by SF 
expression, indicating that FAK-dependent DOX resistance is mediated by p21 in 
cardiomyocytes. (B) Schematic summary of the FAK/p21 signaling axis in resistance to 
DOX cardiotoxicity.
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